Literature DB >> 9920284

Internalisation of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism.

G Pron1, N Mahrour, S Orlowski, O Tounekti, B Poddevin, J Belehradek, L M Mir.   

Abstract

Bleomycin (BLM) does not diffuse through the plasma membrane but nevertheless displays cytotoxic activity due to DNA break generation. The aim of the study was to describe the mechanism of BLM internalisation. We previously provided evidence for the existence of BLM-binding sites at the surface of DC-3F Chinese hamster fibroblasts, as well as of their involvement in BLM cytotoxicity on DC-3F cells and related BLM-resistant sublines. Here we report that A253 human cells and their BLM-resistant subline C-10E also possessed a membrane protein of ca. 250 kDa specifically binding BLM. Part of this C-10E cell resistance could be explained by a decrease in the number of BLM-binding sites exposed at the cell surface with respect to A253 cells. The comparison between A253 and DC-3F cells exposing a similar number of BLM-binding sites revealed that the faster the fluid phase endocytosis, the greater the cell sensitivity to BLM. Moreover, the experimental modification of endocytotic vesicle size showed that BLM cytotoxicity was directly correlated with the flux of plasma membrane area engulfed during endocytosis rather than with the fluid phase volume incorporated. Thus, BLM would be internalised by a receptor-mediated endocytosis mechanism which would first require BLM binding to its membrane receptor and then the transfer of the complex into intracellular endocytotic vesicles, followed by BLM entry into the cytosol, probably from a nonacidic compartment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920284     DOI: 10.1016/s0006-2952(98)00282-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  30 in total

1.  Photochemical internalization-mediated delivery of chemotherapeutic agents in human breast tumor cell lines.

Authors:  Marlon S Mathews; Van Vo; En-Chung Shih; Genesis Zamora; Chung-Ho Sun; Steen J Madsen; Henry Hirschberg
Journal:  J Environ Pathol Toxicol Oncol       Date:  2012       Impact factor: 3.567

Review 2.  Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy.

Authors:  Vicente Muñoz Madero; Gloria Ortega Pérez
Journal:  Clin Transl Oncol       Date:  2011-01       Impact factor: 3.405

3.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

4.  Photochemical internalization of bleomycin for glioma treatment.

Authors:  Marlon S Mathews; Joseph W Blickenstaff; En-Chung Shih; Genesis Zamora; Van Vo; Chung-Ho Sun; Henry Hirschberg; Steen J Madsen
Journal:  J Biomed Opt       Date:  2012-05       Impact factor: 3.170

5.  Electrochemotherapy is effective in the treatment of rat bone metastases.

Authors:  Milena Fini; Francesca Salamanna; Annapaola Parrilli; Lucia Martini; Matteo Cadossi; Melania Maglio; Veronica Borsari
Journal:  Clin Exp Metastasis       Date:  2013-07-07       Impact factor: 5.150

6.  Characterization of a transport and detoxification pathway for the antitumour drug bleomycin in Saccharomyces cerevisiae.

Authors:  Mustapha Aouida; Anick Leduc; Huijie Wang; Dindial Ramotar
Journal:  Biochem J       Date:  2004-11-15       Impact factor: 3.857

7.  Focused ultrasound-mediated sonochemical internalization: an alternative to light-based therapies.

Authors:  Jonathan Gonzales; Rohit Kumar Nair; Steen J Madsen; Tatiana Krasieva; Henry Hirschberg
Journal:  J Biomed Opt       Date:  2016-07-01       Impact factor: 3.170

8.  2-NBDG, a fluorescent analogue of glucose, as a marker for detecting cell electropermeabilization in vitro.

Authors:  Elham Raeisi; Lluis M Mir
Journal:  J Membr Biol       Date:  2012-08-11       Impact factor: 1.843

9.  Isolation and characterization of Saccharomyces cerevisiae mutants with enhanced resistance to the anticancer drug bleomycin.

Authors:  Mustapha Aouida; Omar Tounekti; Anick Leduc; Omrane Belhadj; Lluis Mir; Dindial Ramotar
Journal:  Curr Genet       Date:  2004-03-09       Impact factor: 3.886

10.  Treatment of cancer with cryochemotherapy.

Authors:  L M Mir; B Rubinsky
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.